2024-ASCO-Correlation of therapy-induced neutropenia with survival in patients with metastatic pancreatic cancer treated with GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.
Wednesday, May 29, 2024 BiopharmaWatch Research 1 min read
Key Takeaway: The article discusses a study presented at the 2024 ASCO conference, which investigates the correlation of therapy-induced neutropenia with survival rates in patients with metastatic pancreatic cancer. The study evaluates the efficacy of the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine and nab-paclitaxel. The findings suggest a potential link between neutropenia and improved patient outcomes.
Market Sentiment Analysis
POSITIVE FACTORS
Study explores a novel combination therapy for pancreatic cancer.
Potential correlation between neutropenia and improved survival.
Focus on GSK-3 inhibitor elraglusib shows innovative treatment approach.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
9.4%
average across 4 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
9-ING-41
Phase 2 · Cancer
Full Press Release Details
2024-ASCO-Correlation of therapy-induced neutropenia with survival in patients with metastatic pancreatic cancer treated with GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study. Download PDF View Resource
Frequently Asked Questions
What is the focus of the ASCO 2024 study?
The study focuses on the correlation of therapy-induced neutropenia with survival in metastatic pancreatic cancer patients.
What therapy is being investigated in the study?
The study investigates the GSK-3 inhibitor elraglusib in combination with gemcitabine and nab-paclitaxel.
What is the significance of neutropenia in this study?
Neutropenia may correlate with improved survival rates in patients treated with the studied therapies.
What phase is the study currently in?
The study is in Phase 2, specifically referred to as the 1801 phase 2 study.